Early Detection of Prostate Cancer by Liquid Biopsy

Condition: Prostate Cancer

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT04556916

Sponsor: University Hospital, Montpellier

Eligibility:

Inclusion Criteria:

Patient :
Men over 40 being suspicious of prostate cancer
Subject with PSA ≥ 4 and designated for biopsy
Subjects must be able to attend all scheduled visits and to comply with all trial procedures
mpMRI done before prostate biopsy
Subject must be covered by public health insurance
Signed informed consent form Inclusion Criteria Subject Control Patient patient free from prostatic disease :
Men over 40 with no suspicion of prostate cancer
Subject with PSA < 2.5 and normal digital rectal examination
Subject must be covered by public health insurance
Signed informed consent form Exclusion Criteria Patient :
Subject with histologically confirmed prostate cancer
Subject with a verified viral infection (HIV or Hepatitis)
Subject under Finasteride treatment
Subject under hormonal treatment (analogs, antagonists, androgenics)
Subject with other cancer diagnosed
Subject unable to sign consent
Planned longer stay outside the region that prevents compliance with the visit plan
Subject deprived of liberty, protected adults or vulnerable persons
Urinary infection ≤ 2 months
Subject excluding health insurance registration
Subject refusing to perform prostate biopsy
Subject who are in a dependency or employment with the sponsor or the investigator

Exclusion Criteria:

Patient :
Subject with histologically confirmed prostate cancer
Subject with a verified viral infection (HIV or Hepatitis)
Subject under Finasteride treatment
Subject under hormonal treatment (analogs, antagonists, androgenics)
Subject with other cancer diagnosed
Subject unable to sign consent
Planned longer stay outside the region that prevents compliance with the visit plan
Subject deprived of liberty, protected adults or vulnerable persons
Urinary infection ≤ 2 months
Subject excluding health insurance registration
Subject refusing to perform prostate biopsy
Subject who are in a dependency or employment with the sponsor or the investigator Exclusion Criteria Subject Control :
Subject with histologically confirmed prostate cancer
Subject with a verified viral infection (HIV or Hepatitis)
Subject under Finasteride treatment
Subject with other cancer diagnosed
Subject unable to sign consent
Planned longer stay outside the region that prevents compliance with the visit plan
Subject deprived of liberty, protected adults or vulnerable persons
Urinary infection ≤ 2 months
Subject excluding health insurance registration